AlphAIAlphAI — Financial news for AI agents
globenewswire.comNOV 32 min read

Merck KGaA, Darmstadt, Germany, to Divest CDMO Business to Lonza

Merck KGaA (Germany) agreed to sell its contract development and manufacturing (CDMO) business to Lonza for a mid-triple-digit million-euro amount. The deal, expected to close in mid-2027, will help Merck focus on innovation-driven businesses. Lonza will gain U.S. sites and manufacturing capacity, while Merck will retain other Life Science operations. Both companies aim to ensure a smooth transition for employees and customers.

Original reporting
globenewswire.com
Published Nov 3, 2026, 6:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 7:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck KGaA, Darmstadt, Germany, to Divest CDMO Business to Lonza — source image
Source · globenewswire.com
Decision brief

The 30-second read

Med
01

Why it matters

The transaction reshapes the competitive landscape of contract development and manufacturing, with Lonza emerging as a larger player.

02

Market read

First‑report M&A deal of significant scale in the life‑science sector, likely to affect Lonza's valuation and sector dynamics.

03

What to watch

Potential antitrust scrutiny in the US and Europe may delay closing beyond mid‑2027.

Relevance 8/10Novelty 8/10Timing: today

Background

Merck KGaA is divesting its CDMO unit to focus on core innovation-driven businesses; Lonza gains a strategic asset.

Market effects

Sector

Strengthens the life‑science CDMO sector and may prompt consolidation activity.

Regional

Adds to Lonza's US manufacturing capacity, potentially boosting US biotech supply chains.

Global

Highlights continued M&A activity in the global contract manufacturing space.

Counterpoint

What could challenge this read

Integration risks and financing costs could weigh on Lonza if the deal faces regulatory delays.

Key entities

  • company
    Merck KGaA

    German science and technology firm selling its CDMO business.

  • company
    Lonza

    Swiss contract development and manufacturing organization acquiring the CDMO unit.

Read at source← All news

StoryLonza to acquire Merck KGaA’s five U.S. CDMO sites

Also covered by

6 outlets

Related articles

NOV 3
HighAI 8/10

Lonza buys 5 sites from Germany’s Merck to more than double US footprint

Lonza agreed to buy five U.S. manufacturing sites from Merck KGaA for 100-600 million Swiss francs, expanding its U.S. footprint to nine sites. The deal, expected to close mid-2024, adds 1,100 employees and is projected to generate 250 million francs in annual sales by 2028. Lonza gains cancer and gene therapy production capabilities, while Merck focuses on drug development.

investing.com2 min
NOV 3
MedAI 8/10

Merck KgaA divests US CDMO business to Lonza

Merck KGaA is selling its US contract development and manufacturing organization (CDMO) business to Lonza for an estimated low- to mid-triple-digit million Swiss francs. The deal includes five US sites and around 1,100 employees, expected to close mid-2024. Lonza anticipates $300m in sales from these facilities by 2028. Merck aims to focus on innovation-driven life sciences businesses, according to the company.

manufacturingchemist.com2 min
NOV 3
MedAI 9/10

Merck charts course out of CDMO business with Lonza sale

Merck KGaA is selling its CDMO business to Lonza for a mid-triple-digit million-euro amount, including five US facilities and 1,100 employees. The deal aims to sharpen Merck's life sciences focus and free up resources for other areas, including pharmaceuticals. Lonza expects the acquisition to add $300 million in annual revenue starting in 2028. The transaction is expected to close in mid-2027.

pharmaphorum.com2 min
NOV 3
MedAI 8/10

Lonza to acquire five US manufacturing sites from Merck KGaA

Lonza will acquire five US manufacturing sites from Merck KGaA for low- to mid-triple-digit millions of Swiss francs. The deal, expected to close in mid-2027, will expand Lonza's US presence and add 1,100 employees. The sites focus on various pharmaceutical technologies, with Lonza expecting them to contribute around SFr250m in sales by 2028. The acquisition aligns with Lonza's growth strategy, according to the company.

pharmaceutical-technology.com2 min